NCT04042740 - Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

May 18, 2023

Study Completion Date

August 22, 2023

Conditions

Hepatitis C InfectionHIV Infection

Interventions

DRUG

Glecaprevir/Pibrentasvir (G/P)

Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.

Trial Locations (12)

Weill Cornell Chelsea CRS (7804), New York

Columbia Physicians and Surgeons CRS (30329), New York

Weill Cornell Upton CRS (7803), New York

Whitman-Walker Institute, Inc. CRS (31791), Washington D.C.

Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro

Johns Hopkins Adult AIDS CRS, Baltimore

Unc Aids Crs (3201), Chapel Hill

University of Colorado Hospital CRS (6101), Aurora

Ucsd, Avrc Crs (701), San Diego

University of California, San Francisco HIV/AIDS CRS (801), San Francisco

University of Washington AIDS CRS (1401), Seattle

Massachusetts General Hospital ACTG CRS (101), Boston